4-butyrolactone has been researched along with cyclin d1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, Q; Qiu, TQ; Yang, H | 1 |
| Chen, Y; Ding, J; Gao, Y; Hou, YT; Lin, LP; Zhu, CH | 1 |
2 other study(ies) available for 4-butyrolactone and cyclin d1
| Article | Year |
|---|---|
Ligustilide inhibits vascular smooth muscle cells proliferation.
Topics: 4-Butyrolactone; Animals; Anthracenes; Blotting, Western; Cell Cycle; Cell Proliferation; Cells, Cultured; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Enzyme Activation; Flavonoids; Imidazoles; Male; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Phosphorylation; Pyridines; Rats; Rats, Wistar; Reactive Oxygen Species; Retinoblastoma Protein | 2006 |
Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma.
Topics: 4-Butyrolactone; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin A; Cyclin B; Cyclin B1; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; fas Receptor; Fatty Acid Synthases; Flow Cytometry; G2 Phase; Humans; Immunoprecipitation; Liver Neoplasms; p38 Mitogen-Activated Protein Kinases; Plasmids; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2006 |